What Happened
- Union Minister for Science and Technology Dr. Jitendra Singh proposed the creation of a structured India-Delaware Biomanufacturing Working Group during a meeting with a US delegation led by Delaware Governor Matt Meyer at Seva Teerth, New Delhi
- The proposed working group aims to translate bilateral discussions into concrete collaborations in biomanufacturing research, AI-enabled production processes, next-generation biologics, vaccines, and startup ecosystems
- Singh highlighted India's strengths in cost-efficient pharmaceutical manufacturing and Delaware's proximity to major US pharmaceutical companies and its National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as complementary assets
- Specific areas for cooperation include joint biomanufacturing platforms, translational research bridges between Indian institutions and Delaware research centres, startup and incubation linkages, and co-training in Good Manufacturing Practice (GMP), regulatory science, and quality systems
Static Topic Bridges
India's Biomanufacturing Policy: BioE3 and the Bioeconomy Vision
India has established a comprehensive policy framework for biomanufacturing. The BioE3 Policy (Biotechnology for Economy, Environment, and Employment) was approved by the Union Cabinet to foster high-performance biomanufacturing across health, agriculture, clean energy, and sustainable materials. It targets a $300 billion bioeconomy by 2030 by integrating biotechnology into national missions. The policy merges two earlier central schemes — Biotechnology R&D and Industrial & Entrepreneurship Development — and introduces a new Biomanufacturing and Biofoundry component with a financial outlay of ₹9,197 crore during the 15th Finance Commission period (2021–22 to 2025–26). India's National Biotechnology Development Strategy 2020-2025 set the target of India becoming a top-5 global biomanufacturing hub by 2025 with a $150 billion sector.
- BioE3 Policy: approved by Union Cabinet; managed by Department of Biotechnology (DBT) under Ministry of S&T
- Target: $300 billion bioeconomy by 2030; India ranks 3rd globally in biotech by number of companies
- BioE3 establishes Biomanufacturing & Bio-AI Hubs and Biofoundry centres
- India: world's largest vaccine manufacturer; supplies ~60% of global vaccine demand
- India is the 3rd largest pharmaceutical market by volume, 10th by value; the sector is called "pharmacy of the world"
Connection to this news: The India-Delaware Working Group proposal operationalises BioE3's international cooperation dimension — seeking to combine India's manufacturing scale with Delaware's cutting-edge NIIMBL research infrastructure, targeting the next frontier of AI-enabled, rapid-scale biomanufacturing.
Biotechnology in India: Key Institutions and Programmes
India's biotechnology ecosystem is administered by the Department of Biotechnology (DBT) under the Ministry of Science and Technology. Key institutions include the Biotechnology Industry Research Assistance Council (BIRAC) for industry-academia partnerships and startup support, the National Institute of Immunology (NII), the Centre for Cellular and Molecular Biology (CCMB), the Institute of Genomics and Integrative Biology (IGIB), and the Regional Centre for Biotechnology (RCB). The BioNEST (Bio Incubators Nurturing Entrepreneurship for Scaling Technologies) programme supports biotech startups. India's COVID-19 response — producing Covaxin (BBV152) domestically — demonstrated its biomanufacturing capability at scale.
- BIRAC (Biotechnology Industry Research Assistance Council): promotes research and innovation in biotech startups and industry
- Mission COVID Suraksha: ₹900 crore mission to develop India-made COVID vaccines — led to Covaxin (Bharat Biotech) and Corbevax (Biological E)
- Good Manufacturing Practice (GMP) compliance is mandatory for WHO prequalification — essential for international vaccine supply contracts
- India's biosimilars industry is among the world's most competitive; exporting to regulated markets (US, EU, Japan)
- Pradhan Mantri BioVac Mission and BioAtma Nirbhar Bharat underline biotech self-reliance as a strategic priority
Connection to this news: The proposal's emphasis on co-training in GMP and regulatory science directly addresses the upgrade India needs to move from volume-based generic manufacturing to high-margin, innovation-led biologics and next-generation vaccines.
India-US Science and Technology Cooperation
India-US science and technology cooperation is governed by the India-US Science and Technology Agreement (1966, periodically renewed), the initiative on Critical and Emerging Technologies (iCET) launched in 2023, and the INDUS-X (India-US Defence Acceleration Ecosystem) for defence technology. The US-India Strategic Energy Partnership and the bilateral Cancer Moonshot initiative are specific sectoral cooperations. Sub-national engagements — such as state-to-state science and innovation partnerships — are an increasingly important channel, as illustrated by the India-Delaware biomanufacturing proposal. The iCET framework explicitly covers semiconductor supply chains, AI, quantum computing, biotechnology, and space.
- iCET launched: January 2023, by PM Modi and President Biden; co-led by NSAs of both countries
- iCET covers: semiconductors, AI, quantum computing, advanced telecom (6G), space, and biotechnology
- NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals): a US public-private partnership based in Delaware
- Delaware hosts ~50% of all Fortune 500 company incorporations due to its corporate law; major pharma presence (AstraZeneca US HQ, etc.)
- India-US bilateral trade: approximately $130 billion; US is India's largest single-country export market
Connection to this news: By proposing engagement specifically with Delaware — home to NIIMBL and major pharma companies — India is signalling intent to move the iCET cooperation from broad framework to specific, implementable biomanufacturing partnerships with measurable commercial outcomes.
Key Facts & Data
- BioE3 Policy financial outlay: ₹9,197 crore (15th Finance Commission period, 2021-22 to 2025-26)
- India's bioeconomy target: $300 billion by 2030
- India: world's largest vaccine manufacturer (~60% of global vaccine demand)
- India: 3rd largest pharma market by volume; called "pharmacy of the world"
- NIIMBL: US public-private biomanufacturing innovation institute, based in Delaware
- iCET launched: January 2023 (Modi-Biden); covers biotechnology, semiconductors, AI, quantum
- BIRAC administers industry-academia biotech partnerships and startup support
- Covaxin (BBV152): India's indigenously developed COVID-19 vaccine by Bharat Biotech
- India's biosimilars industry exports to regulated markets in the US, EU, and Japan